5Result: Consensus sequencing confirmed baseline mutations in 6 of the 7 participants identified by OLA, and detected baseline mutations at sites associated with ""potential low-level resistance"" to didanosine and abacavir or ""low-level resistance"" to zidovudine and stavudine in 4 additional participants at codons not evaluated by OLA (
T215T/I, n=1;
T69S, n=1;
T69T/N, n=2) (hivdb.stanford.edu)."
Result: The remaining 6 individuals had mutations at non-OLA codons, all at frequencies <2%, except for 3 individuals: one with
L210W detected at a frequency of 5.9%, and two with
T69N detected; one at a frequency of 22.5% and the second at 25.0% (Figure 3).